[{"data":1,"prerenderedAt":158},["ShallowReactive",2],{"drug-colchicine":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":37,"contraindications":116,"warnings":126,"renal":127,"monitoring":128,"interactions":129,"review":130,"examples":132},"colchicine",1,{"fa":7,"en":8},"کلشی‌سین","Colchicine","analgesics",{"fa":11,"en":12},"ضدالتهاب نقرس","Anti-gout agent",[14],{"name":15,"market":16},"Colcrys","US",[18,19,20,21],"colcrys","کلشیسین","کلشی سین","کلچیسین",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":32,"refs":33},"tab-0-6","tablet","oral","0.6 mg tablet (scored)",{"amount":29,"unit":30,"perUnit":25,"scored":31},0.6,"mg",true,[16],[34],{"source":35,"section":36},"fda-colcrys","3",[38,64,79],{"id":39,"disease":40,"label":41,"population":44,"type":48,"unit":30,"dose":49,"refs":51,"durationDays":54,"notes":55},"flare","gout",{"fa":42,"en":43},"حمله نقرس — ۱٫۲ mg و یک ساعت بعد ۰٫۶ mg","Gout flare — 1.2 mg, then 0.6 mg one hour later",{"minAge":45},{"value":46,"unit":47},18,"year","fixed",{"perDose":50,"dosesPerDay":5},1.2,[52],{"source":35,"section":53},"2.1",{"min":5,"max":5},[56],{"text":57,"refs":60},{"fa":58,"en":59},"در اولین نشانه حمله. در بیمارانی که دوز پیشگیری + مهارکننده CYP3A4 می‌گیرند توصیه نمی‌شود.","At the first sign of a flare. Not recommended in patients on prophylactic dose plus CYP3A4 inhibitors.",[61,62],{"source":35,"section":53},{"source":35,"section":63},"2.4",{"id":65,"disease":40,"label":66,"population":69,"type":48,"unit":30,"dose":72,"refs":73,"limits":75},"prophylaxis",{"fa":67,"en":68},"پیشگیری از حمله نقرس — بالای ۱۶ سال: ۰٫۶ mg یک یا دو بار در روز","Gout flare prophylaxis — >16 y: 0.6 mg once or twice daily",{"minAge":70},{"value":71,"unit":47},16,{"perDose":29,"dosesPerDay":5},[74],{"source":35,"section":53},{"maxPerDay":50,"refs":76},[77],{"source":35,"section":78},"2",{"id":80,"disease":80,"label":81,"population":84,"type":87,"unit":30,"dose":88,"refs":103,"notes":108},"fmf",{"fa":82,"en":83},"FMF — بر اساس سن (۴ سال به بالا)","FMF — by age (≥4 y)",{"minAge":85},{"value":86,"unit":47},4,"ageBand",{"bands":89},[90,95,100],{"minAge":91,"maxAge":92,"perDose":94,"dosesPerDay":5},{"value":86,"unit":47},{"value":93,"unit":47},6,0.3,{"minAge":96,"maxAge":97,"perDose":99,"dosesPerDay":5},{"value":93,"unit":47},{"value":98,"unit":47},13,0.9,{"minAge":101,"maxAge":102,"perDose":50,"dosesPerDay":5},{"value":98,"unit":47},null,[104,106],{"source":35,"section":105},"2.2",{"source":35,"section":107},"2.3",[109],{"text":110,"refs":113},{"fa":111,"en":112},"دوز شروع پایین محدوده: ۴ تا ۶ سال ۰٫۳ تا ۱٫۸؛ ۶ تا ۱۲ سال ۰٫۹ تا ۱٫۸؛ بالای ۱۲ سال و بزرگسال ۱٫۲ تا ۲٫۴ mg\u002Fday، یک یا دو نوبت؛ تغییر ۰٫۳ mg\u002Fday.","Shown is the low end: 4–6 y 0.3–1.8; 6–12 y 0.9–1.8; >12 y and adults 1.2–2.4 mg\u002Fday, once or twice daily; adjust by 0.3 mg\u002Fday.",[114,115],{"source":35,"section":107},{"source":35,"section":78},[117],{"id":118,"severity":119,"text":120,"refs":123},"ci","block",{"fa":121,"en":122},"نارسایی کلیه یا کبد همراه مهارکننده‌های P-gp یا قوی CYP3A4 (سمیت کشنده).","Renal or hepatic impairment together with P-gp or strong CYP3A4 inhibitors (fatal toxicity).",[124],{"source":35,"section":125},"4",[],[],[],[],{"status":131,"reviewer":102,"date":102},"unverified",[133,139,142,147,153],{"regimen":39,"formulation":24,"input":134,"expect":137},{"ageYears":135,"weightKg":136},50,85,{"perDose":50,"tabletsPerDoseRounded":138},2,{"regimen":65,"formulation":24,"input":140,"expect":141},{"ageYears":135,"weightKg":136},{"perDose":29},{"regimen":80,"formulation":24,"input":143,"expect":145},{"ageYears":144,"weightKg":46},5,{"perDose":94,"tabletsPerDoseRounded":146},0.5,{"regimen":80,"formulation":24,"input":148,"expect":151},{"ageYears":149,"weightKg":150},8,25,{"perDose":99,"tabletsPerDoseRounded":152},1.5,{"regimen":80,"formulation":24,"input":154,"expect":157},{"ageYears":155,"weightKg":156},30,70,{"perDose":50},1792078533799]